NO20024044L - Lösning og krystallstrukturer av MMP-13 aktivt sete og anvendelser derav - Google Patents

Lösning og krystallstrukturer av MMP-13 aktivt sete og anvendelser derav

Info

Publication number
NO20024044L
NO20024044L NO20024044A NO20024044A NO20024044L NO 20024044 L NO20024044 L NO 20024044L NO 20024044 A NO20024044 A NO 20024044A NO 20024044 A NO20024044 A NO 20024044A NO 20024044 L NO20024044 L NO 20024044L
Authority
NO
Norway
Prior art keywords
mmp
applications
solution
active site
crystal structures
Prior art date
Application number
NO20024044A
Other languages
English (en)
Other versions
NO20024044D0 (no
Inventor
James Ming Chen
Dominick Mobilio
Franklin J Moy
Kevin D Parris
Robert Powers
Zhang Bao Xu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20024044D0 publication Critical patent/NO20024044D0/no
Publication of NO20024044L publication Critical patent/NO20024044L/no

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N9/00Investigating density or specific gravity of materials; Analysing materials by determining density or specific gravity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489Metalloendopeptidases (3.4.24)
    • C12N9/6491Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24017Stromelysin 1 (3.4.24.17)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
NO20024044A 2000-02-25 2002-08-23 Lösning og krystallstrukturer av MMP-13 aktivt sete og anvendelser derav NO20024044L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/514,026 US6934639B1 (en) 2000-02-25 2000-02-25 Methods for designing agents that interact with MMP-13
PCT/US2001/005150 WO2001063244A1 (en) 2000-02-25 2001-02-16 Solution and crystal structures of mmp-13 active site and uses thereof

Publications (2)

Publication Number Publication Date
NO20024044D0 NO20024044D0 (no) 2002-08-23
NO20024044L true NO20024044L (no) 2002-10-24

Family

ID=24045514

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024044A NO20024044L (no) 2000-02-25 2002-08-23 Lösning og krystallstrukturer av MMP-13 aktivt sete og anvendelser derav

Country Status (16)

Country Link
US (1) US6934639B1 (no)
EP (1) EP1274980A4 (no)
JP (1) JP2003524176A (no)
KR (1) KR20020089362A (no)
CN (1) CN1423748A (no)
AU (1) AU2001241534A1 (no)
BR (1) BR0108684A (no)
CA (1) CA2401063A1 (no)
EA (1) EA200200904A1 (no)
HK (1) HK1052553A1 (no)
HU (1) HUP0301720A2 (no)
IL (1) IL151242A0 (no)
NO (1) NO20024044L (no)
PL (1) PL359819A1 (no)
WO (1) WO2001063244A1 (no)
ZA (1) ZA200206248B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01013171A (es) 2001-02-14 2004-05-21 Warner Lambert Co Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz.
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
MXPA01013172A (es) 2001-02-14 2002-08-21 Warner Lambert Co Inhibidores sulfonamida de metaloproteinasa de matriz.
ES2231708T3 (es) 2001-02-14 2005-05-16 Warner-Lambert Company Llc Benzotiadicinas inhibidoras de metaloproteinasa de matriz.
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
EP1368323B1 (en) 2001-02-14 2010-06-30 Warner-Lambert Company LLC Pyrimidine matrix metalloproteinase inhibitors
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
CA2462442A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
MXPA05001785A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de cromona como inhibidores de las metaloproteinasas de matriz.
BR0313724A (pt) 2002-08-13 2005-06-28 Warner Lambert Co Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
AU2003249477A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
EP1553949B1 (en) 2002-08-13 2007-04-18 Warner-Lambert Company LLC Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014892A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
US7189700B2 (en) * 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds
US11094399B2 (en) * 2011-01-11 2021-08-17 Shimadzu Corporation Method, system and program for analyzing mass spectrometoric data
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
DK3388075T5 (da) 2015-03-27 2024-09-23 Immatics Biotechnologies Gmbh Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
EP4316597A2 (en) 2017-07-07 2024-02-07 immatics biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
US10800823B2 (en) 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331573A (en) * 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6008243A (en) 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use

Also Published As

Publication number Publication date
BR0108684A (pt) 2003-06-24
HK1052553A1 (zh) 2003-09-19
AU2001241534A1 (en) 2001-09-03
PL359819A1 (en) 2004-09-06
ZA200206248B (en) 2003-08-20
IL151242A0 (en) 2003-04-10
KR20020089362A (ko) 2002-11-29
EA200200904A1 (ru) 2003-02-27
HUP0301720A2 (hu) 2003-09-29
JP2003524176A (ja) 2003-08-12
CN1423748A (zh) 2003-06-11
WO2001063244A1 (en) 2001-08-30
NO20024044D0 (no) 2002-08-23
US6934639B1 (en) 2005-08-23
CA2401063A1 (en) 2001-08-30
EP1274980A4 (en) 2005-02-09
EP1274980A1 (en) 2003-01-15

Similar Documents

Publication Publication Date Title
NO20024044D0 (no) Lösning og krystallstrukturer av MMP-13 aktivt sete og anvendelser derav
DE60227300D1 (de) Strukturen von anschlusselementen und anzuschliessende komponente
DE60238206D1 (de) Frequenz- und amplitudenapodisierung von wandlern
ATE258918T1 (de) Kristallform alpha des perindopril-tert- butylaminsalzes
DE60118908D1 (de) Behandlung von mineralischen stoffen
ID30590A (id) Celana sekali pakai jenis-celana pendek
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
DE60225014D1 (de) Pharmazeutische zusammensetzungen von amlodipin und atorvastatin
EE200200393A (et) Glüburiidi ravimkoostis
IS5582A (is) Meta-asahringamínóbensósýrusambönd og afleiður þeirra reynast mótlyf við integríni.
ATE290530T1 (de) Kristalline hydrate von anilid-derivaten als funigizide und insektizide
DE59800287D1 (de) Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
DE60232290D1 (de) Kontrollierte Auflösung von Wirkstoffen
NO20040726L (no) Kombinasjonspreparater av arylsubstituerte propanolaminderivater med andre aktive forbindelser og anvendelse derav.
DK1333817T3 (da) Film til dermal og transdermal indgivelse af aktive bestanddele
NO983666L (no) Krystallmodifikasjon av et farmas°ytisk middel
FR2839237B1 (fr) Structures et proprietes d'elements transducteurs d'harmoniques
DE60017465D1 (de) Kombination aus fluazuron und ivermectin gegen parasiten
DE60141146D1 (de) Adressierung von multistabilen nematischen fluessigkristallvorrichtungen
DE60103685D1 (de) Behandlung von Poriomania
NO20042137L (no) Antranilsyreamider og deres farmasoytiske anvendelse
ATE342890T1 (de) Polymorph v von torasemid
DE69908951D1 (de) Kristallformen von osanetant
DE50113788D1 (de) Strukturierung ferroelektrischer schichten
DK1228026T3 (da) 15-Hydroxyicosatetraensyrerelaterede forbindelser og fremgangsmåde til anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application